Literature DB >> 6312324

Retrovirus transfer of a bacterial gene into mouse haematopoietic progenitor cells.

A Joyner, G Keller, R A Phillips, A Bernstein.   

Abstract

The haematopoietic system is made up of a hierarchy of cells with different developmental, functional and proliferative capacities. Although cellular diversity appears to arise from the commitment and maturation of stem cells, the molecular basis for this differentiation process is unknown. The introduction of cloned DNA sequences into haematopoietic progenitor cells would provide a novel approach for studying this differentiating in vivo system. One laboratory has reported DNA-mediated transfer of genes into mouse bone marrow cells. However, retroviruses offer a number of advantages over DNA-mediated gene transfer procedures, including high efficiency infection of a wide range of cell types in vitro and in vivo, stable and low copy integration into the host chromosome, and a defined integrated provirus structure. For these reasons recombinant DNA techniques have been utilized to construct high efficiency retrovirus vectors expressing foreign genes. We demonstrate here, using such a retrovirus vector, the transfer of a dominant selectable drug-resistance gene into defined classes of mouse haematopoietic progenitor cells. These observations should facilitate the development of molecular genetic approaches to fundamental and clinical problems in haematopoiesis.

Entities:  

Mesh:

Year:  1983        PMID: 6312324     DOI: 10.1038/305556a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  44 in total

1.  Enhancer sequences of a retroviral vector determine expression of a gene in multipotent hematopoietic progenitors and committed erythroid cells.

Authors:  C A Holland; P Anklesaria; M A Sakakeeny; J S Greenberger
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

2.  Identification of immature podocyte specific antigen using retrovirus-mediated gene transfer and cell sorting.

Authors:  Joichi Usui; Mitsujiro Osawa; Satoshi Yamazaki; Yohei Morita; Akio Koyama; Hiromitsu Nakauchi
Journal:  Clin Exp Nephrol       Date:  2005-12       Impact factor: 2.801

Review 3.  Genotoxicity of retroviral hematopoietic stem cell gene therapy.

Authors:  Grant D Trobridge
Journal:  Expert Opin Biol Ther       Date:  2011-03-07       Impact factor: 4.388

4.  Gene transfer to human cells using retrovirus vectors produced by a new polytropic packaging cell line.

Authors:  S A Loiler; N L DiFronzo; C A Holland
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  Expression of retrovirally transduced genes in primary cultures of adult rat hepatocytes.

Authors:  J A Wolff; J K Yee; H F Skelly; J C Moores; J G Respess; T Friedmann; H Leffert
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Characterization of a retrovirus shuttle vector capable of either proviral integration or extrachromosomal replication in mouse cells.

Authors:  S A Berger; A Bernstein
Journal:  Mol Cell Biol       Date:  1985-02       Impact factor: 4.272

7.  H-2Ld antigen encoded by a recombinant retrovirus genome is expressed on the surface of infected cells.

Authors:  J H Weis; C S Reiss; R C Mulligan; S J Burakoff; J G Seidman
Journal:  Mol Cell Biol       Date:  1985-06       Impact factor: 4.272

8.  Expression of human adenosine deaminase in murine hematopoietic cells.

Authors:  J W Belmont; G R MacGregor; K Wager-Smith; F A Fletcher; K A Moore; D Hawkins; D Villalon; S M Chang; C T Caskey
Journal:  Mol Cell Biol       Date:  1988-12       Impact factor: 4.272

9.  Curing genetic disease with gene therapy.

Authors:  David A Williams
Journal:  Trans Am Clin Climatol Assoc       Date:  2014

10.  Transfer and expression of the human multiple drug resistance gene into live mice.

Authors:  S Podda; M Ward; A Himelstein; C Richardson; E de la Flor-Weiss; L Smith; M Gottesman; I Pastan; A Bank
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.